Cosmo Pharmaceuticals (CMOPF) News Today C$62.80 +0.01 (+0.02%) As of 03/31/2025 03:38 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartHeadlinesBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Cosmo Pharmaceuticals Appoints New Chief Legal CounselApril 1 at 2:03 AM | tipranks.comCosmo Pharmaceuticals publishes Annual Report 2024March 27, 2025 | theglobeandmail.comCosmo Pharmaceuticals reports FY resultsMarch 21, 2025 | seekingalpha.comFull Year 2024 Cosmo Pharmaceuticals NV Earnings Call TranscriptMarch 7, 2025 | gurufocus.comCosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and ...March 7, 2025 | gurufocus.comCosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across PortfolioFebruary 11, 2025 | finance.yahoo.comCosmo names Andrea Cherubini as chief AI officerFebruary 11, 2025 | msn.comGlenmark, Cosmo get MHRA nod for acne treatment medicationFebruary 10, 2025 | msn.comCosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of AcneFebruary 10, 2025 | finance.yahoo.comCosmo, Glenmark secure UK MHRA approval of Winlevi for treatment of acneFebruary 10, 2025 | msn.comKepler Capital Sticks to Its Buy Rating for COSMO Pharmaceuticals N.V. (0RGI)January 11, 2025 | markets.businessinsider.comCosmo Pharmaceuticals Appoints Chief Strategy OfficerDecember 12, 2024 | finance.yahoo.comCosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGMOctober 19, 2024 | stockhouse.comCosmo Pharmaceuticals Appoints New Chief Financial OfficerOctober 11, 2024 | stockhouse.comCosmo Pharmaceuticals NV (CMOPF) (H1 2024) Earnings Call Highlights: Revenue Surge and ...October 9, 2024 | finance.yahoo.comCosmo Chemical Co LtdSeptember 20, 2024 | reuters.comCMOPF Cosmo Pharmaceuticals N.V.September 7, 2024 | seekingalpha.comFree food, endless TV and… the flu? This is what it’s like to take part in a paid medical trialAugust 11, 2024 | msn.comCosmo Intelligent Medical Devices Unveils Next Generation GI Genius(TM) Hardware with New FDA ClearanceJuly 31, 2024 | finance.yahoo.comCosmo Pharmaceuticals N.V. (CMOPF)July 26, 2024 | ca.finance.yahoo.comCosmo Pharmaceuticals NV's Dividend AnalysisMay 27, 2024 | finance.yahoo.comCosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General MeetingMay 24, 2024 | finance.yahoo.comCosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023April 29, 2024 | finance.yahoo.comDespite concern about older adults living alone, these seniors prefer the solo life: 'I love not having to answer to anyone else'April 29, 2024 | msn.comCosmo Announces Leadership ChangesApril 25, 2024 | finance.yahoo.comQ4 2023 Paysign Inc Earnings CallMarch 28, 2024 | finance.yahoo.comBullish: Analysts Just Made A Massive Upgrade To Their Cosmo Pharmaceuticals N.V. (VTX:COPN) ForecastsMarch 28, 2024 | finance.yahoo.comCosmo Pharmaceuticals N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMarch 23, 2024 | finance.yahoo.comCosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per ShareMarch 20, 2024 | finance.yahoo.comCosmo Pharmaceuticals Announces Approval of Winlevi(R) in AustraliaMarch 19, 2024 | finance.yahoo.comSay Hi to the Cosmo Trend Report: A Comprehensive Look at All the Things You’re Gonna Want to Wear This SpringMarch 15, 2024 | msn.comCosmo Pharmaceuticals (VTX:COPN) shareholders have endured a 18% loss from investing in the stock three years agoMarch 13, 2024 | finance.yahoo.comGibson to open huge guitar store in West End on SaturdayFebruary 23, 2024 | msn.comPupils unwell after school lab chemical spillFebruary 22, 2024 | au.news.yahoo.comCosmo Pharmaceuticals N.V.February 20, 2024 | wsj.comCosmoprof North America Miami Celebrates Its Inaugural Edition with Overwhelming Success with over 19,000 VisitsFebruary 1, 2024 | markets.businessinsider.comInvitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024January 25, 2024 | finance.yahoo.comBrokers Are Upgrading Their Views On Cosmo Pharmaceuticals N.V. (VTX:COPN) With These New ForecastsJanuary 5, 2024 | finance.yahoo.comCosmo Pharmaceuticals N.V. (VTX:COPN) Stocks Shoot Up 37% But Its P/S Still Looks ReasonableDecember 18, 2023 | finance.yahoo.comMarket Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues Pushing Shares 37% HigherDecember 18, 2023 | finance.yahoo.comCosmo Pharmaceuticals NV CMOPFNovember 23, 2023 | morningstar.comCosmo Pharmaceuticals N.V.'s (VTX:COPN) top owners are private companies with 47% stake, while 35% is held by individual investorsNovember 23, 2023 | finance.yahoo.comCosmo Pharmaceuticals (VTX:COPN) shareholders have endured a 68% loss from investing in the stock five years agoOctober 5, 2023 | finance.yahoo.comCosmo, Glenmark Sign Distribution And License Agreements For Winlevi In Europe, South AfricaSeptember 27, 2023 | msn.comCosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South AfricaSeptember 27, 2023 | benzinga.comCOSMO Pharmaceuticals SA (COPN)September 16, 2023 | investing.comCosmo Pharmaceuticals N.V.'s (VTX:COPN) P/E Still Appears To Be ReasonableSeptember 14, 2023 | finance.yahoo.comCosmo Pharmaceuticals (VTX:COPN) shareholders have endured a 58% loss from investing in the stock five years agoSeptember 14, 2023 | finance.yahoo.comCosmo Pharmaceuticals N.V.'s (VTX:COPN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?September 14, 2023 | finance.yahoo.comCosmo Pharmaceuticals N.V. (VTX:COPN) Is About To Go Ex-Dividend, And It Pays A 2.0% YieldSeptember 14, 2023 | finance.yahoo.com Remove Ads Get Cosmo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CMOPF and its competitors with MarketBeat's FREE daily newsletter. Email Address CMOPF Media Mentions By Week CMOPF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMOPF News Sentiment▼0.000.78▲Average Medical News Sentiment CMOPF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMOPF Articles This Week▼20▲CMOPF Articles Average Week Remove Ads Get Cosmo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CMOPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AstraZeneca News Today JCR Pharmaceuticals News Today Kyowa Kirin News Today Mayne Pharma Group News Today Ono Pharmaceutical News Today Otsuka News Today Roche News Today Sanofi News Today Scilex News Today Virbac News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTC:CMOPF) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cosmo Pharmaceuticals Please log in to your account or sign up in order to add this asset to your watchlist. Share Cosmo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
